...
首页> 外文期刊>European Journal of Pharmacology: An International Journal >Antihyperalgesic effect of levetiracetam in neuropathic pain models in rats.
【24h】

Antihyperalgesic effect of levetiracetam in neuropathic pain models in rats.

机译:左乙拉西坦在大鼠神经性疼痛模型中的抗痛觉过敏作用。

获取原文
获取原文并翻译 | 示例
           

摘要

The purpose of this study was to assess, in rats, the antinociceptive effects of levetiracetam (i.p.), a novel antiepileptic drug, in acute pain tests and in two models of human neuropathic pain. Levetiracetam and carbamazepine contrasted morphine by an absence of effect in the tail flick and hot plate tests. In normal rats, carbamazepine failed to modify the vocalisation thresholds to paw pressure whereas levetiracetam slightly increased this threshold only at the highest dose (540 mg/kg) for 30 min. In the sciatic nerve with chronic constriction injury model, the highest dose of levetiracetam (540 mg/kg) and carbamazepine (30 mg/kg) reversed the hyperalgesia. In streptozocin-induced diabetic rats, levetiracetam dose-dependently increased the vocalization threshold from 17 to 120 mg/kg reaching a similar effect as 10 mg/kg of carbamazepine. These results indicate that levetiracetam induces an antihyperalgesic effect in two models of human neuropathic pain, suggesting a therapeutic potential in neuropathic pain patients.
机译:这项研究的目的是在大鼠中评估新型抗癫痫药左乙拉西坦(i.p.)在急性疼痛测试和两种人类神经性疼痛模型中的镇痛作用。左乙拉西坦和卡马西平对比吗啡,因为在尾部甩动和热板测试中没有作用。在正常大鼠中,卡马西平未能将发声阈值修改为爪压,而左乙拉西坦仅在最高剂量(540 mg / kg)下持续30分钟才稍微提高该阈值。在具有慢性收缩损伤的坐骨神经中,最高剂量的左乙拉西坦(540 mg / kg)和卡马西平(30 mg / kg)逆转痛觉过敏。在链脲佐菌素诱导的糖尿病大鼠中,左乙拉西坦剂量依赖性地将发声阈值从17 mg / kg增加到120 mg / kg,达到与10 mg / kg卡马西平相似的作用。这些结果表明左乙拉西坦在两种人类神经性疼痛模型中均具有抗痛觉过敏作用,表明在神经性疼痛患者中具有治疗潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号